These findings suggest that inhibiting aberrant SC-EV production, interfering with SC-derived miR-142-5p expression, and modulating hippocampal ACTN4, ELAVL4, and USP9X expression may be potentially practical therapeutic approaches for preventing and treating CNP-associated memory impairment. The gene discussed is ACTN4; the disease is memory impairment.